Mr Kamada has a life sciences and pharmaceuticals practice for clients based in Japan, the United States, the UK, the rest of Europe, Australia, Israel, China, Taiwan and Korea. He has directed prosecution of patent families covering over 50 countries, but his main work relates to prosecution, opposition and appeal procedures before the Japan Patent Office (JPO), as well as litigations before the IP High Court. He has handled more than 60 opposition and appeal proceedings before the JPO and their High Court appeals over the course of his carrier to date. Recent technologies he has been involved with include advanced life sciences such as regenerative medicine (e.g., stem cell technologies), cancer immunotherapy (e.g., TCR and CAR-T technologies, immune checkpoint inhibitors), gene therapy (e.g., genome editing, viral cancer therapy, DNA vaccine), nucleic acid medicine (e.g., antisense oligonucleotide, siRNA, miRNA, aptamer), antibodies (e.g., antibody medicine, diagnosis, human antibody production system), gene diagnosis (e.g., epigenetic diagnosis, metagenome analysis), biomarkers and the like, pharmaceuticals (e.g., new chemical compounds, second medical use, pharmaceutical compositions, new dosage form), biomaterials (e.g., culture medium, culture device, DDS carrier), bioinformatics, AI-technologies for medicine and drug discovery, foods and cosmetics.
With extensive experience in formulating patent strategies and managing patent portfolios, Mr Kamada counsels and renders opinions on patent validity, patent infringement and patent or knowhow licensing. He also counsels clients on freedom-to-operate issues.
Mr Kamada provides a number of lectures for IP members and researchers in pharmaceutical companies, universities, research institutes and other organizations related to IP in Japan on how to patent biotechnology inventions. He has also published articles in IP journals in Japan.
Mr Kamada graduated from Kyoto University with B.S. degrees in biology and chemistry, and then pursued graduate studies on molecular biology and genetic engineering at Hiroshima University. He joined TAKASHIMA International Patent Office in 1995, became Head of the Biotechnology Department in 2000 and has served as President of the firm since 2019.